Abstract
Background
As new treatment and research advances continue to improve the prognosis of cancer patients, oncologists and surgeons are increasingly faced with the issue of fertility protection and preservation. Cancer patients are frequently exposed to gonadotoxic chemotherapy and radiation therapy as a component of their treatment regimens. There are currently various anticipatory techniques available to women who wish to retain future reproductive ability, the most successful of which involves oocyte retrieval followed by in vitro fertilisation and embryo cryopreservation. Innovative methods include oocyte cryopreservation, ovarian follicle cryopreservation and oophoropexy.
Aim
The aim of this study was to examine our combined experiences at Mayo General Hospital of treating female patients (<30 years) with non-gynaecologic malignancy and requiring referral to the HARI Unit during a 6-year period (2007–2012). Emphasis was placed on reviewing the fertility-preservation options available.
Methods
The hospital inpatient enquiry system was inspected for all cases of non-gynaecologic malignancy referred for fertility preservation from 2007 to 2012.
Results
Three cases of non-gynaecologic malignancy in young females, with an intention to protect and preserve future fertility were identified. The primary treatment plan did not initially incorporate input from a gynaecology or fertility specialist. It was after concerted inquiry and reflection by both physician and patient that oncofertility consultation was sought.
Conclusion
The responsibility is on both physicians and surgeons to consider a more holistic approach to cancer care in young female patients, which focuses not only on the elimination of malignancy but also on preservation of fertility and quality of life.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armuand GM, Rodriguez-Wallberg KA, Wettergren L et al (2012) Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 30:2147
Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729
Blumenfeld Z (2007) How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist 12:1044–1054
Casper RF, Mitwally MF (2006) Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91:760–771
Chen C (1986) Pregnancy after human oocyte cryopreservation. Lancet 1:884–886
Clough KB, Goffinet F, Labib A et al (1996) Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Cancer 77:2638–2645
European Cancer Organisation: pregnancy is safe for women with oestrogen receptor positive breast cancer. Available at http://www.ecco-org.eu/Global/News/EBCC8-PR/2012/03/21_03-Pregnancy-is-safe-for-women-with-oestrogen-receptor-positive-breast-cancer.aspx. Accessed 2 Dec 2012
Irsan I, Akisue T, Hara H et al (2007) Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res 27:423–429
Jeruss JS, Woodruff TK (2009) Preservation of fertility in patients with cancer. N Engl J Med 360:902–911
Matsuo G, Ushijima K, Shinagawa A et al (2007) GnRH agonist acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Kurume Med J 54:25–29
Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Human Reprod Updat 7:535–543
Meistrich ML, Shetty G (2008) Hormonal suppression for fertility preservation in males and females. Reproduction 136:691–701
National Multiple Sclerosis Society, novantrone (mitoxantrone): Available at http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/medications/mitoxantrone/index.aspx. Accessed 2 Dec 2012
Noyes N, Porcu E, Borini A (2009) Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 18:769–776
Oktay K, Sonmezer M (2004) Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 19:477–480
Oktay K, Buyuk E, Veeck L et al (2004) Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 363:837–840
Paik S, Shak S, Tang G et al (2004) Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826
Parra SA (2000) Cytotoxic chemotherapy in the treatment of nonmalignant disease. J Intraven Nurs 23:359–365
Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785
Schmidt KL, Andersen CY, Loft A et al (2005) Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 20:3539–3546
Tao T, Zhang W, Del Valle A (2009) Human oocyte cryopreservation. Curr Opin Obstet Gynecol 21:247–252
Woodruff TK, Snyder KA (2007) Oncofertility: fertility preservation for cancer survivors. Springer, New York
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Smyth, C., Robertson, I., Higgins, L. et al. Fertility preservation in young females with non-gynaecologic malignancy: an emerging speciality. Ir J Med Sci 183, 33–38 (2014). https://doi.org/10.1007/s11845-013-0967-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-013-0967-1